| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/PRP2.911 |
| P50 | author | Richard Head | Q39271470 |
| Jennifer Martin | Q44551189 | ||
| Kirsty G. Pringle | Q55153495 | ||
| Eugenie Lumbers | Q56249815 | ||
| Bevyn Jarrott | Q91195124 | ||
| P2860 | cites work | Toxicology of Melatonin | Q22299302 |
| Antioxidants that protect mitochondria reduce interleukin-6 and oxidative stress, improve mitochondrial function, and reduce biochemical markers of organ dysfunction in a rat model of acute sepsis | Q24622152 | ||
| Pericytes: developmental, physiological, and pathological perspectives, problems, and promises | Q27026645 | ||
| Melatonin and its analogs in insomnia and depression | Q28249175 | ||
| Melatonin: shedding light on infertility?--A review of the recent literature | Q28917092 | ||
| Melatonin as a potential therapy for sepsis: a phase I dose escalation study and an ex vivo whole blood model under conditions of sepsis | Q34788841 | ||
| The role of Keap1 in cellular protective responses | Q36344046 | ||
| Oxidative stress and mitochondrial dysfunction in sepsis: a potential therapy with mitochondria-targeted antioxidants. | Q37581872 | ||
| The nuclear factor (erythroid-derived 2)-like 2 (Nrf2) activator dh404 protects against diabetes-induced endothelial dysfunction. | Q37679215 | ||
| The Keap1-Nrf2-antioxidant response element pathway: a review of its regulation by melatonin and the proteasome. | Q38295523 | ||
| Cellular and molecular mechanisms of statins: an update on pleiotropic effects | Q38451245 | ||
| Aging-related decline in the induction of Nrf2-regulated antioxidant genes in human bronchial epithelial cells | Q38597772 | ||
| The mitochondria-targeted antioxidant MitoQ protects against organ damage in a lipopolysaccharide-peptidoglycan model of sepsis. | Q39930840 | ||
| Pharmacological activation of endogenous protective pathways against oxidative stress under conditions of sepsis | Q40868414 | ||
| Safety of melatonin in long-term use (?) | Q40875387 | ||
| The IUPHAR/BPS Guide to PHARMACOLOGY in 2018: updates and expansion to encompass the new guide to IMMUNOPHARMACOLOGY. | Q47139831 | ||
| New perspectives on the role of melatonin in human sleep, circadian rhythms and their regulation | Q47557441 | ||
| Melatonin and structurally similar compounds have differing effects on inflammation and mitochondrial function in endothelial cells under conditions mimicking sepsis. | Q48256568 | ||
| The Crosstalk between Nrf2 and Inflammasomes | Q50042104 | ||
| The role of Nrf2 in NLRP3 inflammasome activation | Q50053963 | ||
| Circadian modulation of neuroplasticity by melatonin: a target in the treatment of depression. | Q52670419 | ||
| The Timing of Melatonin Administration Is Crucial for Its Antidepressant-Like Effect in Mice | Q58800989 | ||
| Modulating NRF2 in Disease: Timing Is Everything | Q59701095 | ||
| The absolute bioavailability of oral melatonin | Q73961833 | ||
| How to RECOVER from RENAISSANCE? The significance of the results of RECOVER, RENAISSANCE, RENEWAL and ATTACH | Q78482942 | ||
| NLRP3 Gene Deletion Attenuates Angiotensin II-Induced Phenotypic Transformation of Vascular Smooth Muscle Cells and Vascular Remodeling | Q89696064 | ||
| Circadian Rhythm and Melatonin in the Treatment of Depression | Q90732532 | ||
| THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Introduction and Other Protein Targets | Q91226596 | ||
| Microvascular pericytes in brain-associated vascular disease | Q91340543 | ||
| Short-term pharmacological activation of Nrf2 ameliorates vascular dysfunction in aged rats and in pathological human vasculature. A potential target for therapeutic intervention | Q91854697 | ||
| Melatonin Attenuates LPS-Induced Acute Depressive-Like Behaviors and Microglial NLRP3 Inflammasome Activation Through the SIRT1/Nrf2 Pathway | Q92058771 | ||
| Recent developments in research of melatonin and its potential therapeutic applications | Q92652830 | ||
| EV71 virus reduces Nrf2 activation to promote production of reactive oxygen species in infected cells | Q94453242 | ||
| Obesity could shift severe COVID-19 disease to younger ages | Q94538338 | ||
| Real-time tracking of self-reported symptoms to predict potential COVID-19 | Q94562621 | ||
| Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19 | Q95294644 | ||
| SARS-CoV-2 infection and overactivation of Nlrp3 inflammasome as a trigger of cytokine "storm" and risk factor for damage of hematopoietic stem cells | Q96127261 | ||
| Redox-Modulating Agents in the Treatment of Viral Infections | Q96294441 | ||
| SARS-CoV-2 Entry Receptor ACE2 Is Expressed on Very Small CD45- Precursors of Hematopoietic and Endothelial Cells and in Response to Virus Spike Protein Activates the Nlrp3 Inflammasome | Q97637388 | ||
| A metabolic handbook for the COVID-19 pandemic | Q97643797 | ||
| COVID-19 is, in the end, an endothelial disease | Q98940025 | ||
| Long covid: How to define it and how to manage it | Q99207263 | ||
| Non-neuronal expression of SARS-CoV-2 entry genes in the olfactory system suggests mechanisms underlying COVID-19-associated anosmia | Q99555412 | ||
| Melatonin Is a Feasible, Safe, and Acceptable Intervention in Doctors and Nurses Working Nightshifts: The MIDNIGHT Trial | Q102065384 | ||
| Understanding COVID-19: in the end it is the endothelium-what else? | Q102215637 | ||
| Can Melatonin Be a Potential "Silver Bullet" in Treating COVID-19 Patients? | Q103790184 | ||
| New proposal involving nanoformulated melatonin targeted to the mitochondria as a potential COVID-19 treatment | Q103838424 | ||
| Hyperactivation of P2X7 receptors as a culprit of COVID-19 neuropathology | Q104486623 | ||
| Therapeutic approaches against coronaviruses acute respiratory syndrome | Q104618957 | ||
| Post-acute COVID-19 syndrome | Q106292557 | ||
| Role of the Renin–Angiotensin–Aldosterone and Kinin–Kallikrein Systems in the Cardiovascular Complications of COVID-19 and Long COVID | Q108591796 | ||
| SARS CoV-2 related microvascular damage and symptoms during and after COVID-19: Consequences of capillary transit-time changes, tissue hypoxia and inflammation | Q111271220 | ||
| Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection | Q111911145 | ||
| Network medicine links SARS-CoV-2/COVID-19 infection to brain microvascular injury and neuroinflammation in dementia-like cognitive impairment | Q112611481 | ||
| P433 | issue | 1 | |
| P921 | main subject | long covid | Q100732653 |
| P577 | publication date | 2022-01-13 | |
| P1433 | published in | Pharmacology Research & Perspectives | Q27725410 |
| P1476 | title | “LONG COVID”—A hypothesis for understanding the biological basis and pharmacological treatment strategy | |
| P478 | volume | 10 |
| Q128955425 | Traumatic Brain Injury in the Long-COVID Era | cites work | P2860 |
Search more.